The global antifungal agent market is anticipated to grow at a considerable CAGR of 3.1% during the forecast period (2022-2028). Product innovations coupled up with many leading advancements in antifungal agent are anticipated to drive the market in the coming years. Antifungal treatments, both topical and oral medicines such as creams, sprays, tablets, and injections, are commercially offered in a wide range of formulations so according to the requirement and convenience, they can be used. Another factor driving the growth of this market is the rise in disposable income. Middle-class families have increased their healthcare spending as their disposable income rises, allowing them to receive better care. Moreover, there are increasing investments that are made to continue research and development operations for the development of anti-fungal medications is expected to fuel market growth. In addition, growing awareness among patients and healthcare professionals is propelling the antifungal agent market.
Browse the full report description of “Global Antifungal Agent Market Size, Share & Trends Analysis Report By Drug Class (Polyene, Echinocandins, Allylamines, and Azole), By Dosage Type (Powder, Ointment and Drugs), and By Route Of Administration (Parental, Topical and Oral) Forecast 2022-2028” at https://www.omrglobal.com/industry-reports/antifungal-agent-market
The antifungal agent market is also driven by key players who continued to focus on the development of new generic and unique anti-infective pharmaceuticals and formulation technologies to address serious fungal infections. The different launches made by many major companies include, for instance, in September 2021, Scynexis Inc. announced the availability of BREXAFEMME, which is the first and only oral non-azole therapy option for vaginal yeast infections and it will also be provided on cloud-based pharmacies. It is a new treatment against candida species, it disrupts the fungal cell wall and kills the fungi that cause the illness rather than just slowing it down.
In October 2021, Intas Pharmaceuticals Ltd., launched the antifungal drug Itraconazole-SB. The medicine is intended to lower the cost of fungal infection treatment while simultaneously improving patient compliance and reducing doctor counselling time. Itraconazole molecule has low blood drug concentration, affecting safety and efficacy when taken orally.
Market Coverage
• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Drug Class
o By Dosage Type
o By Route of Administration
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- including Gilead Sciences, Inc., Merck& Co., Inc., Novartis AG, Pfizer Inc., Sanofi, and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Antifungal Agent Market Report Segment
By Drug Class
By Dosage Type
By Route of Administration
Global Antifungal Agent Market Report Segment by Region
North America
• U.S.
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/antifungal-agent-market